$0.61
(Market cap
$6,899 Mln
Revenue (TTM)
$763 Mln
P/E Ratio
134.4
P/B Ratio
3.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
50.52
-
EV/EBITDA
38.4
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$0.9
-
Face value
--
-
Shares outstanding
56,407,740
10 Years Aggregate
CFO
$626.05 Mln
EBITDA
$681.59 Mln
Net Profit
$511.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
| -18.3 | 15.6 | 12.3 | 1.5 | -6.2 | -6.9 | 19.1 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
| 13.8 | -19.8 | 6.2 | -36.1 | 38.2 | 107.2 | 75.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Repligen (RGEN)
|
133.9 | 6,899.2 | 763.3 | 51.4 | 11.7 | 2.5 | 134.4 | 3.3 |
| 87.9 | 158,626.9 | 45,134.0 | 6,276.0 | 15.4 | 12.2 | 25.5 | 3.0 | |
| 47.0 | 72,608.5 | 20,615.0 | 3,553.0 | 19.9 | 14.5 | 20.4 | 2.7 | |
| 180.3 | 127,957.8 | 24,778.0 | 3,689.0 | 18.7 | 7.1 | 35.1 | 2.4 | |
| 84.8 | 49,495.8 | 6,303.5 | 1,092.8 | 12.7 | 10.6 | 46.5 | 4.9 | |
| 557.9 | 44,344.9 | 4,446.1 | 1,095.2 | 23.5 | 70.3 | 41.3 | 28.5 | |
| 408.4 | 149,478.0 | 10,582.1 | 2,979.1 | 22.4 | 17.2 | 51.3 | 8.6 | |
| 80.4 | 105,188.7 | 36,364.0 | 4,800.0 | 13.3 | 19.6 | 22 | 1.9 | |
| 313.8 | 115,472.1 | 25,270.0 | 3,337.0 | 18.5 | 15.1 | 34.9 | 4.9 | |
| 470.3 | 179,132.7 | 45,197.0 | 6,859.0 | 19.2 | 13.3 | 26.5 | 3.4 |
Shareholding Pattern
View DetailsAbout Repligen (RGEN)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM... chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Read more
-
CEO & Director
Mr. Anthony J. Hunt
-
CEO & Director
Mr. Anthony J. Hunt
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Repligen (RGEN)
What is the current share price of Repligen Corporation (RGEN) Today?
The share price of Repligen Corporation (RGEN) is $133.94 (NASDAQ) as of 12-Jun-2026 13:41 EDT. Repligen Corporation (RGEN) has given a return of -6.18% in the last 3 years.
What is the current PB & PE ratio of Repligen Corporation (RGEN)?
The P/E ratio of Repligen Corporation (RGEN) is 134.41 times as on 05-Jun-2026, a 166 premium to its peers’ median range of 50.52 times.
The P/B ratio of Repligen Corporation (RGEN) is 3.26 times as on 05-Jun-2026, a 4 discount to its peers’ median range of 3.38 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
189.42
|
4.40
|
|
2024
|
-316.25
|
4.09
|
|
2023
|
241.38
|
5.09
|
|
2022
|
51.99
|
5.06
|
|
2021
|
119.15
|
8.73
|
What is the 52 Week High and Low of Repligen Corporation (RGEN)?
The 52-week high and low of Repligen Corporation (RGEN) are Rs 175.77 and Rs 100.99 as of 13-Jun-2026.
What is the market cap of Repligen Corporation (RGEN)?
Repligen Corporation (RGEN) has a market capitalisation of $ 6,899 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Repligen Corporation (RGEN)?
Before investing in Repligen Corporation (RGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.